Journal of Prevention and Infection Control Open Access

  • ISSN: 2471-9668
  • Journal h-index: 6
  • Journal CiteScore: 1.11
  • Journal Impact Factor: 1.04
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days

Adverse events in patients with multi drug resistant tuberculosis: results of a prospective cohort study at tertiary care level

8th Edition of International Conference on Infectious Diseases
June 07-08, 2018 London, UK

Gupta G, Sharma S K, Sinha S,Soneja M and Jorwal P

All India Institute of Medical Sciences, India

Posters & Accepted Abstracts: J Prev Infect Cntrol

Abstract:

Introduction: Drug-resistant tuberculosis (DR-TB) is a global public health crisis. According to Global Tuberculosis report 2017, treatment success rates of multi-drug-resistant tuberculosis (MDR-TB) and extensively drug-resistant TB (XDR-TB) patients are 46% and 29%. Henceforth one of the major obstacles in achieving successful treatment outcomes in DR-TB is adverse events affecting the adherence to the both first-line and secondline drugs. Aim: To evaluate the frequency of adverse events due to the second-line drugs in MDR-TB patients during intensive phase of treatment. Settings & Design: A prospective cohort study was conducted at DOTS Plus site at AIIMS, New Delhi. 81 consecutive MDRTB patients were recruited from June 2014 to May 2015 and were given standardized revised national control tuberculosis programme (RNCTP) drug-regimen. Patients were followed-up during intensive phase of treatment and adverse events were
primarily recognized with clinical evidence and/or laboratory investigations. Results: A total of 91 adverse events were reported in 52 (64.1%) patients. Only 1.2% of the patient stopped treatment and 9.8% required removal of the suspected drug(s) from the regimen due to adverse events. The grouped adverse events were most commonly gastrointestinal (70.6%), arthralgia (10.9%), ototoxicity (6.4%), psychiatric (5.5%), and hypothyroidism (2.1%). Nine (11%) patients had serious adverse events requiring discontinuation or substitution of drugs that included psychiatric disturbances in 6(7.4%) followed by hearing loss and tinnitus in 3(3.7%). Conclusions: In India, programmatic management of drug resistance tuberculosis guidelines (PMDT) provides guidance for management of DR-TB but cure rate are undesirable and one of the major issue to be catered is adherence which can assure for successful treatment outcomes.

Email:drgaurav996@gmail.com